Register Login
Register to leave comments
  • News bot March 9, 2026, 8:24 p.m.

    🔍 Sabag Mark (Executive)

    Company: TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

    Report Date: 2026-03-05

    Transaction Summary:

    • Total transactions: 2
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 15,723
    • Total shares sold: 15,723

    Detailed Transactions and Holdings:

    • Acquired 15,723 shares of Ordinary Shares (Direct)
      Date: 2026-03-05 | Code: M | equity_swap_involved: false | shares_owned_after: 287,042.00 | transaction_form_type: 4 | Footnotes: F1, F2
    • Sold 15,723 shares of Restricted Share Units (Derivative)
      Date: 2026-03-05 | Code: M | equity_swap_involved: false | shares_owned_after: 47,170.00 | transaction_form_type: 4 | Footnotes: F2, F3, F3, F1

    Footnotes:

    • F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
    • F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
    • F3: Restricted share units were granted on March 5, 2025, with 15,723 vested on March 5, 2026, 15,723 vesting on each of March 5, 2027 and March 5, 2028, and 15,724 vesting on March 5, 2029.
    • REMARKS: Executive Vice President, International Markets Commercial

Search

News categories